SPRY News & Analysis
2 articles
Market Mood
Spyre Therapeutics (SPRY) Director Albers Sells $2.4M in Stock
Spyre Therapeutics director Albers sold $2.4 million worth of stock recently. This sale may signal the director's personal financial moves rather than reflect on the company's performance. While insider selling can sometimes prompt investor concern, it's important to view such transactions in context. Investors should monitor any further moves from company insiders that might affect perceptions of Spyre Therapeutics (SPRY).
Read More: Spyre Therapeutics (SPRY) Director Albers Sells $2.4M in Stock
ARS Pharmaceuticals (SPRY) Names Donn Casale as New CEO
ARS Pharmaceuticals Inc. (NASDAQ: SPRY) appointed Donn Casale as CEO, effective July 7, succeeding co-founder Richard Lowenthal, who left the company on July 6. Casale has over 25 years of experience in biopharma, including previous roles at Dynavax Technologies, where he helped grow annual revenues for the HEPLISAV-B vaccine to over $300 million. Additionally, on June 24, the company reported no new coverage decisions for its epinephrine nasal spray, neffy, during the July 1 formulary cycle. This leadership transition may impact the company's strategic direction and market opportunities for neffy.
Read More: ARS Pharmaceuticals (SPRY) Names Donn Casale as New CEO